Further randomized controlled trials are needed to fully understand the efficacy and safety profiles of ECMO in SA/NFA. MP is being widely used to achieve safer ventilation, and although more data is required, it appears to be a promising option for evaluating the risk of developing VILI and the success of the therapy.
Keyphrases
- extracorporeal membrane oxygenation
- respiratory failure
- acute respiratory distress syndrome
- randomized controlled trial
- mechanical ventilation
- chronic obstructive pulmonary disease
- electronic health record
- lung function
- big data
- allergic rhinitis
- clinical trial
- machine learning
- stem cells
- meta analyses
- data analysis
- cell therapy
- replacement therapy